Rethinking the diagnosis of von Willebrand disease

Thrombosis Research

Volumn 127, Issue SUPPL. 2, 2011, Pages

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Collagen binding; DDAVP; Desmopressin; Diagnosis; Genetic testing; von Willebrand disease; VWD

Indexed keywords

COLLAGEN BINDING PROTEIN; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GENETIC ANALYSIS; HUMAN; MEDICAL ERROR; PHENOTYPE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

BLOOD COAGULATION TESTS; DEAMINO ARGININE VASOPRESSIN; DIAGNOSTIC ERRORS; HUMANS; PHENOTYPE; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 78650767407     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70149-3     Document Type: Article

References (25)

1. JE Sadler, U Budde, JC Eikenboom, EJ Favaloro, FG Hill, L Holmberg Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor J Thromb Haemost 4 2006 2103 2114
2. EJ Favaloro Identification and functional characterisation of von Willebrand Disease US Hematology 2 1 2009 16 23
3. EJ Favaloro Towards a new paradigm for the identification and functional characterisation of von Willebrand disease Semin Thromb Hemost 35 2009 60 75
4. EJ Favaloro An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult Semin Thromb Hemost 33 2007 727 744
5. EJ Favaloro, M Krigstein, J Koutts, T Brighton, R Lindeman Genetic testing for the diagnosis of von Willebrand Disease: benefits and limitations J Coag Disorders 2 2010 37 47
6. EJ Favaloro Genetic testing for von Willebrand disease: the case against J Thromb Haemost 8 2010 6 12
7. F Rodeghiero, A Tosetto, T Abshire, DM Arnold, B Coller, P James ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders J Thromb Haemost 8 9 2010 Sep 2063 2065
8. EJ Favaloro, G Lippi, M Franchini Contemporary platelet function testing Clin Chem Lab Med 48 5 2010 May 579 598
9. M Othman, EJ Favaloro Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype? Semin Thromb Hemost 34 2008 520 531
10. AB Federici, PM Mannucci, G Castaman, L Baronciani, P Bucciarelli, MT Canciani Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients Blood 113 3 2009 526 534
11. AS Ribba, I Loisel, JM Lavergne, I Juhan-Vague, B Obert, G Cherel Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen Thromb Haemost 86 3 2001 848 854
12. AF Riddell, K Gomez, CM Millar, G Mellars, S Gill, SA Brown Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor Blood 114 16 2009 Oct 15 3489 3496
13. VH Flood, CA Lederman, JS Wren, PA Christopherson, KD Friedman, RG Hoffmann Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD J Thromb Haemost 8 2010 1431 1432
14. EJ Favaloro, S Mohammed, J Koutts Identification and prevalence of von Willebrand Disease type 2N (Normandy) in Australia Blood Coag Fibrinolysis 20 2009 706 714
15. JE Sadler Low von Willebrand factor: sometimes a risk factor and sometimes a disease Hematology Am Soc Hematol Educ Program 106-12 2009
16. EJ Favaloro, J Thom, R Baker, on behalf of the Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: Results from the second Australasian multi-laboratory survey Blood Coag Fibrinolysis 11 2000 729 738
17. EJ Favaloro, R Bonar, K Marsden, on behalf of the RCPA QAP Haemostasis Committee Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification Clin Lab Sci 21 2008 178 185
18. EJ Favaloro, G Lippi, DM Adcock Preanalytical and postanalytical variables: The leading causes of diagnostic error in haemostasis? Semin Thromb Hemost 34 2008 612 634
19. EJ Favaloro, R Bonar, M Meiring, A Street, K Marsden, on behalf of the RCPA QAP in Haematology 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of Type 2B VWD Thromb Haemost 98 2007 346 358
20. EJ Favaloro, R Bonar, G Kershaw, J Sioufi, R Baker, M Hertzberg on behalf of the RCPA QAP in Haematology Reducing errors in identification of von Willebrand disease: The experience of the Royal College of Pathologists of Australasia Quality Assurance Program Semin Thromb Hemost 32 2006 505 513
21. P Meijer, F Haverkate An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation Semin Thromb Hemost 32 5 2006 485 491
22. EJ Favaloro Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD) - a rebuttal J Thromb Haemost 6 2008 1999 2001
23. EJ Favaloro, J Thom, D Patterson, S Just, T Dixon, J Koutts Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 123 2009 862 868
24. EJ Favaloro, J Thom, D Patterson, S Just, M Baccala, T Dixon Potential supplementary utility of combined PFA-100 and functional VWF testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease Blood Coag Fibrinolysis 20 2009 475 483
25. F Rodeghiero, G Castaman, A Tosetto Optimizing treatment of von Willebrand disease by using phenotypic and molecular data Hematology Am Soc Hematol Educ Program 2009 113 123